By IDSE New Staff
The antiviral drug tecovirimat (Tpoxx, SIGA Technologies) did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international STOMP trial.
Therefore, the study’s data safety and monitoring board (DSMB) recommended stopping further enrollment of participants who were being randomized to tecovirimat or placebo. The